Mel-Mont Medical develops patented n-Vintro mRNA technology devices for the early detection of High-Risk Human Papilloma Virus (HR-HPV), which is linked to cervical and other HPV-related cancers. Their molecular screening services aim to enhance preventive healthcare by enabling timely interventions and improving patient outcomes.
Funding
$50K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
High-Risk Human Papilloma Virus (HR-HPV) is linked to cervical and other HPV-related cancers, necessitating early and accurate detection for effective prevention and treatment. Traditional screening methods may lack the sensitivity needed for early identification, potentially delaying timely interventions and impacting patient outcomes.
Solution
Mel-Mont Medical develops and commercializes patented n-Vintro mRNA technology devices and molecular screening services for the early detection of HR-HPV. Their offerings include medical devices, in vitro diagnostics, and sample preparation reagents designed to enhance preventive healthcare. The company's molecular assays for nucleic acid amplification, coupled with an ISO 13485-certified HPV-mRNA molecular laboratory service, provide reliable and clinically validated results. By focusing on early detection, Mel-Mont Medical aims to empower individuals to take control of their health through proactive prevention strategies.
Target Audience
The primary target audience includes healthcare providers, laboratories, and individuals seeking advanced molecular screening for the early detection of HR-HPV and prevention of HPV-related cancers.
Features
- Patented n-Vintro mRNA technology for HR-HPV detection
- Medical devices designed for user-friendly and safe operation
- In vitro diagnostics with molecular assays for nucleic acid amplification
- ISO 13485-certified HPV-mRNA molecular laboratory service
- Sample preparation reagents for efficient and cost-effective molecular testing
- Clinically validated molecular biology technologies